Science First: The Future of Personalized Medicine in Psychiatry – the Special Role of Genes & Phenotypes
Science First: The Future of Personalized Medicine in Psychiatry – the Special Role of Genes & Phenotypes
JLABS @ TMC , John P. McGovern Campus , Houston , TX 77021
June 01, 2016 from 17:00 PM to 20:00 PM (CDT)
$10 - $35
The tailoring of medical decisions, practices, and therapeutic interventions to individual patients based upon their predicted response or risk of disease/illness will be an essential component of future healthcare practice. This will require a precise understanding of molecular & cellular basis of their clinical disorder. It will necessitate the development of biomarkers to define illness subtypes and primary outcome measures will be needed for clinical trials comprised of symptom rating scales that are less susceptible to rater and participant bias. In the context of Mood disorders, which are among the most common medical disorder with lifetime prevalence rates ranging from 14% to 16% for major depressive disorder (MDD), the WHO ranks MDD as the highest global cause of "years of life lost due to illness or disability" on a population basis, and projects that in 2030 MDD also will rank first in global disease burden, as measured in Disability Adjusted Life Years (DALYs). Mood disorders also are associated with elevated mortality rates, especially due to suicide and cardiovascular disease.
Our ultimate goal is to move therapeutic interventions to earlier stages of illness, modify disease course, and improve prognosis. The success of such disease interception strategy will depend on identifying early or prodromal disease detection in high risk populations and affords a vision toward a world without disease.
Johnson & Johnson Innovation, JLABS (JLABS) is bringing in the experts from across neuroscience to discuss the challenges and opportunities in the field. Hear from folks who are leading the science, investing in the technology, and those who bring a broad perspective on the future of healthcare.
3:00 PM | Registration Opens and Networking
3:15 PM | Presentations
4:15 PM | Panel Discussion
5:00 PM | Networking Reception
6:00 PM | Program Close
Lynda Chin | Assoc Vice Chancellor and Chief Innovation Officer, The University of Texas System read bio»
Jimmy Holder | Child Neurologist, Baylor College of Medicine and Texas Children's Hospital read bio»
Thomas Kosten | Professor of Psychiatry, Neuroscience, Pharmacology, and Immunology, Baylor College of Medicine read bio»
Consuelo Walss-Bass | Associate Professor, Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center at Houston read bio»
[moderator] Guy Seabrook | Vice President, Neuroscience Innovation, J&J Innovation read bio»
$25 | General Public
$15 | Student/Academic
$35 | At the door
About the Science First series:
The purpose of the Science First series, sponsored by Johnson & Johnson Innovation, JLABS, is to bring together top experts to explore a pressing topic in their scientific field. It is a chance for local scientists, researchers, and entrepreneurs to present and dialogue on new discoveries, advancing techniques, and other cutting-edge science themes.
JLABS @ TMC
John P. McGovern Campus
2450 Holcombe Blvd, Suite J
Houston, TX 77021
Please park in the self parking areas of the McGovern Campus. Grab a Token at the gate and bring it to the event space. We encourage carpooling and using the TMC shuttles.
Lynda Chin, M.D. | Associate Vice Chancellor and Chief Innovation Officer, The University of Texas System
Dr. Lynda Chin, M.D. served as a Scientific Co-Founder of Metamark Genetics, Inc. Dr. Chin co-founded Aveo Pharmaceuticals Inc. in 2002. She is the Associate Vice Chancellor and Chief Innovation Officer at the University of Texas System. At the Broad Institute of Harvard and MIT, Dr. Chin is the PI of a TCGA Genome Data Analysis Center. She is actively involved in The Cancer Genes Atlas (TCGA) Project, a member of its Executive Subcommittee, and chairs the GBM and Melanoma Disease Working Groups that interface the genomic science within TCGA with basic and translational biology in the broader community. At Dana-Farber Cancer Institute and Harvard, she served as the Scientific Director of Dana-Farber's Belfer Institute for Applied Cancer Science and co-led the DF/HCC Melanoma Program and the Harvard Skin SPORE. Dr. Chin serves as a Member of the Department of Adult Oncology at the Dana-Farber Cancer Institute of Harvard Medical School. She serves as a Member of Scientific Advisory Board of Aveo Pharmaceuticals, Inc. She serves as a Member of Watson Healthcare Advisory Board of International Business Machines Corp. She served as a Member of Scientific Advisory Board at Karyopharm Therapeutics, Inc. She served as a Director of Metamark Genetics, Inc. until December 2012. Dr. Chin was a Professor of Dermatology at the Harvard Medical School. She was an Assistant Professor of Dermatology at the Harvard Medical School. She is a leader in the field of melanoma genetics and has pioneered the construction and use of mouse models of melanoma. She is a recognized expert in the use of genomics to identify cancer-relevant genes and directs a cancer genomics facility for the Dana-Farber Cancer Institute. She pioneered the concept of tumor maintenance and the use of second-site suppression genetics in mammalian systems. She chairs the Skin Organ Site Committee of the Mouse Models of Human Cancer Consortium (MMHCC) of the National Cancer Institute. In addition to her many contributions in the area of melanoma genetics and modeling, Dr. Chin focuses on comparative oncogenomics of mouse and human cancers, and integration of functional genetic approaches to accelerate the translation of genomic insights into clinical endpoints. She is also a member of the Scientific Steering Committee of the International Cancer Genome Consortium. She is the recipient of numerous scientific awards including the V Foundation Scholar Award, the BASF Research Award, the Culpeper Award, and the Rising Star's Award. In 2000, she also received the Stone Wilson Award for Cancer Research. She conducted her medical training at Columbia Presbyterian Medical Center and the Albert Einstein College of Medicine, where she was Chief Resident of Dermatology. She is a board-certified Dermatologist. Dr. Chin received her M.D. from the Albert Einstein College of Medicine in 1993. She holds a M.D. from The University of Texas.
Connect with Lynda:
Jimmy L. Holder, Jr. M.D., Ph.D. | Child Neurologist, Baylor College of Medicine and Texas Children's Hospital
Jimmy L. Holder, Jr. M.D., Ph.D. is a child neurologist at Baylor College of Medicine and Texas Children's Hospital. He is also a physician scientist at the Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital. He is a graduate of Johns Hopkins University with a degree in biology. At Hopkins, he began his research interest in the lab of Andrew Warren in the Department of Psychiatry. From Hopkins, Dr. Holder moved to the University of Texas Southwestern Medical School where he obtained both his MD and PhD in human genetics. His graduate work was under the mentorship of Andrew Zinn where he identified a novel genetic cause of obesity. This was followed by a post-doctoral fellowship at the University of California at San Francisco in the laboratory of Louis Ptacek in Neurogenetics where he participated in identifying a genetic determinant of human sleep homeostasis. Following this post-doctoral fellowship, he came to Baylor College of Medicine as a child neurology resident. Following completion of his residency, he was a clinical research fellow with Huda Zoghbi where he participated in identification of SHANK3 overexpression as a cause of manic-like behavior in mice and bipolar disorder in patients. He is currently an assistant professor in the Department of Pediatrics, Division of Neurology and Developmental Neuroscience where he is continuing his research of the genetics of neuropsychiatric and neurodevelopmental disorders.
Thomas R. Kosten, M.D. | Professor of Psychiatry, Neuroscience, Pharmacology, and Immunology, Baylor College of Medicine
Dr. Kosten is the JH Waggoner Chair and Professor of Psychiatry, Pharmacology, Immunology and Neuroscience, vice-Chair for Psychiatry and Co-director of the Dan L. Duncan Institute for Clinical and Translational Research (ICTR) at Baylor College of Medicine. He is the founding Vice Chair for Addiction Psychiatry of the American Board of Psychiatry and Neurology, and Past President of both the American Academy of Addiction Psychiatry (AAAP) and the College on Problems of Drug Dependence (CPDD). He is a Distinguished Life Fellow in the American Psychiatric Association (APA) and a Fellow of the American College of Neuropsychopharmacology (ACNP). He has served as a Congressional Fellow in the US House of Representatives and has been a long-standing member of various substance abuse commissions for the National Academy of Sciences (NAS) as well as various advisory boards for the Food and Drug Administration (FDA) and the Department of Defense (DOD). He is the current Editor for the American Journal on Addictions, past Editor for the American Journal of Drug and Alcohol Abuse, and serves on the board of several notable journals in substance abuse. He has published over 650 papers, books, and reviews describing his contributions, particularly in the use of pharmacotherapeutics for treating cocaine and opioid addictive disorders as well as his work in vaccine development for cocaine and methamphetamine addictions.
Consuelo Walss-Bass, Ph.D. | Associate Professor, Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center at Houston
Consuelo Walss-Bass, Ph.D. received a Bachelor of Science degree in chemical engineering from the Instituto Tecnologico de la Laguna, Torreon, Mexico. She went on to receive a Master's of Science degree in chemistry from the University of Texas at San Antonio and then earned a Doctor of Philosophy degree in biochemistry from the University of Texas Health Science Center at San Antonio (UTHSCSA). Afterwards she trained in psychiatric genetics at the UTHSCSA. In 2005 she joined the faculty in the Division of Genetics in the UTHSCSA Dept. of Psychiatry, and since 2014 is Associate Professor at the University of Texas Health Science Center at Houston, where she is the Director of the Psychiatric Genetics Program. Dr. Walss-Bass' research focuses on the understanding of psychiatric disorders at the molecular level. She utilizes genomic and proteomic techniques in human and animal models to correlate genetic variations with cellular function in order to understand the molecular mechanisms that are involved in development and expression of mental illnesses. In addition, Dr. Walss-Bass is interested in the study of the mechanism of action of antipsychotic medications, in particular antipsychotic-induced metabolic syndrome, as it may lead to an understanding of the cellular processes involved in metabolic disorders. As director of the Psychiatric Genetics Program, Dr. Walss-Bass helps psychiatry investigators develop research to correlate behavioral outcomes with genetic underpinnings and biological mechanisms. Dr. Walss-Bass is also actively involved in teaching endeavors. She has mentored a number of undergraduate, graduate and post-graduate students that have worked in her laboratory. Dr. Walss-Bass is strongly committed to educating the community on the biological causes of mental disorders, to reduce the stigma associated with these illnesses. She believes that putting a "biological face" onto these disorders will help the community at large in viewing these disorders as they do cancer or diabetes.
Connect with Consuelo:
[moderator] Guy Seabrook, Ph.D. | Vice President, Neuroscience Innovation, Johnson & Johnson Innovation
Guy joined Janssen Pharmaceutical Companies of Johnson & Johnson in 2012. His role as the Neuroscience Lead for Johnson & Johnson Innovation Center in California is to help co-create and implement the external innovation plan to deliver the Neuroscience Therapeutic Area R&D Strategy. This includes solidifying Janssen's place as an ideal partner in a highly competitive landscape of external collaborations. Our goals are to identify the best opportunities for value-generating collaborations and develop an industry-leading portfolio of investment opportunities. This involves the cultivation of a strong scientific network of experts in the global innovation community. He has >25 years drug discovery research that includes preclinical research on marketed products and candidates in clinical development. Formerly, Guy was part of Eli Lilly's Global External Research & Development organization where he led the GER&D team for the Lilly Bio-Medicines Business Unit, and also at Merck & Co, Inc where he was the Head of the West Point Department of Alzheimer's Disease Research. He graduated with a Ph.D. in Zoology from the University of Nottingham UK (1987), and completed his postdoctoral research at the University of Miami School of Medicine USA.
Connect with Guy: